Well, That Was a Wild Week
Insights - Depending how you were positioned, this last week was one of the most entertaining, educational, and wild of the year. And the sell the news phenomenon … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Headlines Aren’t Helping Healthcare Stocks
Research - Despite an onslaught of ominous headlines -- allegations of fraud at Valeant Pharamceuticals (VRX) and continued backlash over increasing drug prices -- biotech stocks have held steady over the last month.
Premium
Bluebird Bio Drops on Patient “Relapse” and Other Biotech Updates
Research - Shares of bluebird bio (BLUE) tumbled 15% mid-day when the company said at a medical conference that a beta-thalassemia patient who received Lentiglobin’s predecessor therapeutic … Continue Reading
PremiumIt Takes an Iron Stomach to Invest in Biotech Stocks
Insights - That was apparent yet again this week, with a slew of binary events that moved stocks in unexpected ways. Beginning with Zafgen (ZFGN). The developer … Continue Reading
Read now
Cempra’s Phase 3 Hit Its Primary Endpoints, But Not Without Caveats
Research - Positive top-line results from SOLITAIRE-IV, with some confounding safety outcomes, had Cempra Inc (CEMP) trading down on Friday morning by 25%.
Premium
Transition Calls Latest Cut of Alzheimer’s Data Positive
Research - Transition Therapeutics (TTHI) said in a press release Thursday morning that after further review of the failed phase 2/3 study of ELND005 in Alzheimer's disease patients with agitation and aggression, the company identified a sub-population in which patients saw a significant clinical benefit on ELND00.
PremiumAlmost Two Months From the Top, Where Are We Now?
Research - We're nearly two months into the equity markets' deepest correction since August 2011. The S&P 500 bounced handily from its August lows at the end of September, and this week is close to retesting its latest level of resistance.
Premium